The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. · 2023
Read The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. by Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10060155.txt.
Introduction
Issa and a large trial team report on revumenib, a drug that blocks the menin protein, in leukemia with certain gene changes, in a 2023 study. The target cancers carry either a rearranged KMT2A gene or a mutated NPM1 gene. Both forms depend on menin to keep cancer growth programs switched on.
The paper reports trial results in patients whose disease had returned or resisted other care. It describes responses to the drug and its side effects. The work supports a new class of targeted drugs for hard-to-treat acute leukemia.
Catalog record
| CREATOR | Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia By Ghayas C. Issa, Ibrahim Aldoss, John DiPersio, Branko Cuglievan, Richard Stone, Martha Arellano, Michael J. Thirman, Manish R. Patel, David S. Dickens, Shalini Shenoy, Neerav Shukla, Hagop Kantarjian Published in: Nature DOI: 10.1038/s41586-023-05812-3 ABSTRACT Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function1–3. The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A or mutation of the nucleophosmin 1 gene (NPM1)4–6. KMT2A rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas NPM1 mutations occur in up to 30%, forming the most common genetic alteration in acute myeloid leukaemia7,8. Here, we describe the results of the first-in-human phase 1 clinical trial investigating revumenib (SNDX-5613), a potent and selective oral inhibitor of the menin–KMT2A interaction, in patients with relapsed or refractory acute leukaemia (ClinicalTrials.gov, NCT04065399). We show that therapy with revumenib was associated with a low frequency of grade 3 or higher treatment-related adverse events and a 30% rate of complete remission or complete remission with partial haematologic recovery (CR/CRh) in the efficacy analysis population. Asymptomatic prolongation of the QT interval on electrocardiography was identified as the only dose-limiting toxicity. Remissions occurred in leukaemias refractory to multiple previous lines of therapy. We demonstrate clearance of residual disease using sensitive clinical assays and identify hallmarks of differentiation into normal haematopoietic cells, including differentiation syndrome. These data establish menin inhibition as a therapeutic strategy for susceptible acute leukaemia subtypes. MAIN The prognosis of acute leukaemias harbouring rearrangements of the gene lysine methyltransferase 2A (KMT2A), previously known as mixed-lineage leukaemia (MLL), is poor, with a 5-year overall survival of less than 25% (ref. 7). KMT2A rearrangements (KMT2Ar) occur in 80% of infant acute lymphoblastic leukaemia (ALL) and in 5–15% of children and adults with acute leukaemia, whether myeloid, lymphoid or mixed phenotype9. Mutated nucleophosmin 1 gene (NPM1) is the most common genetic alteration in adult acute myeloid leukaemia (AML), occurring in up to 30% of patients8. Currently there are no targeted therapies specifically approved for acute leukaemia with KMT2Ar or mutated NPM1. Genetic rearrangements of KMT2A lead to aberrant expression of homeobox (HOX) genes and their DNA-binding cofactor MEIS1 (ref. 10). This gene expression programme, normally expressed in stem cells, causes a haematopoietic differentiation block and leukaemic transformation11. For leukaemias driven by KMT2Ar, menin is a critical oncogenic cofactor4. The menin-binding motif is preserved throughout all KMT2A fusion proteins, and menin is an essential cofactor for binding to HOX gene promoters7. Similarly, in AML with mutated NPM1, the interaction between wild-type KMT2A and menin leads to HOX- and MEIS1-mediated leukaemogenic transcription6,12. Blockade of the menin–KMT2A interaction disrupts the assembly of oncogenic KMT2A wild-type or fusion complexes on chromatin12. Preclinical studies showed that menin inhibition downregulates HOX and MEIS1 transcription and reverses leukaemogenesis in KMT2Ar-r- or NPM1-mutated leukaemia models5,12,13. Revumenib, previously known as SNDX-5613, is a potent, oral, selective inhibitor of the menin–KMT2A interaction. Treatment with revumenib led to abrogation of aberrant HOX gene expression and dramatic antileukaemic activity in those models (Extended Data Fig. 1; GEO accession no. for RNA sequencing (RNA-seq) data, GSE216730). In this first-in-human clinical trial we assessed the safety, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D) and pharmacokinetic and pharmacodynamic profiles in patients with relapsed or refractory acute leukaemia, and present the clinical activity of revumenib in patients with KMT2Ar or mutated NPM1. This phase 1 dose-escalation study was conducted across nine sites in the United States. Because revumenib is a substrate of cytochrome P450 3A4 (CYP3A4), two parallel dose-escalation cohorts, one without (Arm A) and one with (Arm B) strong CYP3A4 inhibitors, were conducted. Revumenib was administered orally every 12 h (q12h) in continuous 28-day cycles. Although all patients could enrol at study initiation regardless of cytogenetic and mutational profile, given the strong preclinical rationale demonstrating that the menin–KMT2A interaction is a targetable vulnerability in acute leukaemia with KMT2Ar or mutated NPM1, an early amendment to the protocol restricted enrolment to patients with relapsed or refractory acute leukaemia with KMT2Ar or mutated NPM1 (88% of the total study population). Between 5 November 2019 and 31 March 2022, a total of 68 patients (37 in Arm A and 31 in Arm B) were enroled and treated. The data cutoff date for this analysis was 31 March 2022. Patient disposition is presented in Extended Data Fig. 2. Baseline characteristics of patients are provided in Extended Data Table 1. There were 56 patients (82%) with relapsed or refractory AML, 11 (16%) with ALL and one with mixed-phenotype acute leukaemia (2%). Forty-six patients (68%) had KMT2Ar, 14 (21%) had mutated NPM1 and eight (12%) had neither KMT2Ar nor NPM1 mutations. Sixty patients were adults (at least 18 years old) and eight were children or adolescents (under 18 years of age). The median age was 42.5 years (range, 0.8–79). The median age of adult patients was 50.5 years (range, 19–79) and the median age among paediatric patients was 2.5 years (range, 0.8–16). The study population was heavily pretreated with a median of four previous lines of therapy (range, 1–12), and 31 patients (46%) had relapsed after an allogenic stem cell transplant. All patients who received at least one dose of revumenib were included in the safety analysis whereas only patients with KMT2Ar or mutated NPM1 were included in the efficacy analysis. The dose-escalation schema is shown in Extended Data Fig. 3. The only dose-limiting toxicity observed in both Arm A and Arm B was grade 3 prolongation of the QT interval (over 500 ms) on electrocardiography (ECG), a toxicity predicted in preclinical animal studies. These events occurred without any clinical correlate or symptoms. This dose-limiting toxicity was observed in Arm A at dose levels of 226 mg q12h (n = 1) and 339 mg q12h (n = 2), and in Arm B at 113 mg q12h (n = 1) and 226 mg q12h (n = 2). The incidence of grade 3 QT prolongation was 10% at dose levels either at or below MTD. A total of 67 treated patients (99%) had an adverse event during treatment with revumenib whereas 53 patients (78%) had a treatment-related adverse event (TRAE) of any grade (Table 1). The most frequent treatment-emergent adverse events (TEAEs) of any grade, irrespective of a relationship to revumenib, were prolongation of the QT interval (56%), nausea (50%), vomiting (40%) and febrile neutropenia (31%); a full listing of these adverse events in at least 20% of the patients is given in Table 1. The most frequent TEAEs of grade 3 or higher were febrile neutropenia (31%), thrombocytopenia (19%) and sepsis (18%) (Extended Data Table 2). The most frequent TRAE was prolongation of the QT interval, in 36 patients (53%). Eleven patients (16%) had grade 3 or 4 TRAEs (Extended Data Table 2). The most frequent grade 3 TRAE was prolongation of the QT interval, in nine patients (13%). There were no ventricular arrythmias, and all episodes of grade 3 QT prolongation resolved either before the next dose or with protocol-directed dose hold. All patients with grade 3 QT prolongation were able to resume dosing at the next-lower dose